[Experience with prostate-specific antigen in patients with prostatic cancer].
The authors investigated 71 prostatic cancer patients and 45 BPH patients. The serum concentration of prostatic specific antigen (PSA), the prostatic acid phosphatase (PAP) by radio-immunoassay, the same enzyme (SPP) and the total acid phosphatase (SP) by enzymatic method were determined. In the untreated cancer patients the PSA concentration proved to be pathological in a higher proportion in all stage groups comparing to the results of the PAP, SPP, SP. The clearing of the PSA and PAP concentration on the following days and months after the beginning of the therapy reflects the excellent monitoring capability of the PSA determination. This was demonstrated by several cases too. The authors suggest more frequent use of this method in clinical practice.
Romics
I
I
Bach
D
D
D000135:Acid Phosphatase / Q000097:blood; D000941:Antigens / Q000276:immunology*; D014408:Biomarkers, Tumor; D000939:Epitopes; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D011467:Prostate / Q000276:immunology; D011470:Prostatic Hyperplasia / Q000201:enzymology / Q000276:immunology*; D011471:Prostatic Neoplasms / Q000201:enzymology / Q000276:immunology*; D011863:Radioimmunoassay
D000941:Antigens; D014408:Biomarkers, Tumor; D000939:Epitopes; D000135:Acid Phosphatase
A prostata specifikus antigénnel szerzett tapasztalataink prostatadaganatos betegekben.